Erdem Barış ÇATI, LEVENT YENİAY, Murat ALTUNTAŞ

SENTİNEL LENF NODU BİYOPSİSİ KLİNİK SONUÇLARI VE NOMOGRAMIN KULLANILABİLİRLİĞİ

Giriş: Bu retrospektif çalışmayı sentinel lenf nodu risk faktörlerini veMemorial Sloan-Kettering Cancer Center(MSKCC) nomogramının kendi hasta grubumuzda kullanılabilirliğini incelemek amacıyla planladık. Gereç ve yöntem: 740 hastamızın dosyaları retrospektif olarak incelendi. Her hastanın sonuçları MSKCC grubunun 2003’de hazırladığı sentinel lenf nodu için tahmin nomogramına girilerek SLN tahmin değeri alındı. ROC analizi ile klinik olarak kullanılabilirliği incelenmiştir. Bulgular: Mutivarite analiz sonucumuza göre prognostik faktör olabilecek değişkenlerimiziçinden lenfovasküler invazyon, yaş ve progesteron reseptörü sentinel lenf nodu metastazı ileilişkili bulunmuştur.ROC curve eğrisinin altında kalan alan 0.749 olarak bulunmuştur. Bu değer MSKCC SLN tahmin nomogramının bizim hasta grubumuz için kullanışlı olduğunu göstermektedir Tartışma: MSKCC SLN nomogramının kullanışlı olduğunu ve %17.5 cut-off değeri ile sentinel lenf nodu biyopsi ihtiyacı kalmadan hastanın aksiler lenf nodu negatif hasta olarak kabul edilip, hastanın evrelendirilebileceği söylenebilir.

THE RESULTS OF SENTINEL LYMPH NODE BIOPSY AND THE VALIDITY OF NOMOGRAM

Introduction: In this retrospective study we aimed to assess if the risk factors and MSKCC nomogram can be used in predicting the axillary metastasis in our patient group Materials and Methods: The records of 740 patients treated in our hospital were retrospectively investigated. The Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram was applied for each patient and the clinical validity was assessed by ROC analysis. Results: The multivariate analyses revealed that lymphovasculary invasion, age and progesteron receptor were related to sentinel lymph node metastasis. The ROC AUC was calculated as 0.749. These results show that MSKCC SLN nomogram can be used in our patient group. Discussion: We can assert that MSKCC SLN nomogram is a useful tool and the patient can be considered as axillary lymph node negative patient without any requirement for sentinel lymph node biopsy when the cut-off value is considered as 17.5%.

PDF

___

1. Bevilacqua JL, Kattan MW, Fey JV, Cody HS, III, Borgen PI, VanZee KJ. Doctor, what are my chances of having a positive sentinel node. A validated nomogram for risk estimation. J Clin Oncol2007; 25(24): 3670–9.
2. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14(4):297–05.
3. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW et al. Surgical complications associated with sentinel lymph node dissection (SLND) plusaxillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25(24): 3657–63.
4. WilkeLG, McCallLM, PostherKE, WhitworthPW, ReintgenDS, LeitchAM, et. al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13(4): 491–00.
5. Lee AHS, Ellis IO, Pinder SE. Pathological assessment of sentinel lymph node biopsies inpatients with breast cancer. Virchows Arch 2000;436(2): 97-101.
6. Weaver DL. Pathological evaluation of sentinel lymph nodes in breast cancer: a practical academic perspective from America. Histopathology 2005; 46(6): 702-6.
7. Van Zee KJ, Manasseh DM, Bevilacqua JL. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003; 10(10): 1140–51.
8. Qiu PF, Liu JJ, Wang YS, Yang GR, Liu YB, Sun X et al. Sentinel lymph node metastasis and validation study of the MSKCC Nomogram in breast Cancer Patients.Jpn J Clin Oncol 2012;42(11):1002–07.
9. Klar M, Foeldi M, Markert S, Gitsch G, Stickeler E, Watermann D. Good prediction of the likelihood for sentinel lymph node metastasis by using the MSKCC nomogram in a german breast cancer population. Ann Surg Oncol 2009;16(5):1136–42.
10. Patani NR, Dwek MV, Douek M. Predictors of axillary lymph node metastasis in breast cancer:A systematic review. Eur J Surg Oncol 2007;33: 409–19.